Contraceptive methods with scheduled bleeding effects
AssigneeEstetra Srl
InventorsJean-Michel FOIDART, Maud JOST
Life of this patent
Estimating the term…
Abstract
Described are methods of providing contraception with increased likelihood of scheduled bleeding in a woman having a BMI<30.0 kg/m2 and methods of providing contraception with reduced likelihood of scheduled bleeding in a woman having a BMI≥30.0 kg/m2. The methods comprise orally administering a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also provided are compositions comprising an estetrol component and drospirenone for use in such methods.
Claims17
(canceled)
A method of providing contraception with reduced likelihood of scheduled bleeding in a woman having a BMI≥30.0 kg/m2, comprising:
- selecting a woman determined to have a BMI≥30.0 kg/m2, and then
- orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg,
- wherein the method comprises administration according to consecutive 28-day cycles of daily administration of the estetrol component and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of the estetrol component and drospirenone on consecutive days 25-28,
- wherein the treated woman has a reduced likelihood of scheduled bleeding on day 25 to day 3 of consecutive 28-day cycles.
(canceled)
A method of providing contraception with an increased likelihood of scheduled bleeding in a woman having a BMI<30.0 kg/m2, comprising:
- selecting a woman determined to have a BMI<30.0 kg/m2, and then
- orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg,
- wherein the method comprises administration according to consecutive 28-day cycles of daily administration of the estetrol component and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of the estetrol component and drospirenone on consecutive days 25-28,
- wherein the woman has an increased likelihood of scheduled bleeding on any of day 25 to day 3 of consecutive 28-day cycles.
Dependencies are inferred from the claim text.